肺癌微转移的检测及其临床意义

Detection and clinical significance of micrometastasis in patients with lung cancer

微转移是手术后非小细胞肺癌复发的关键因素。常规方法和技术难以发现这些隐匿性的癌细胞,运用分子生物学等敏感技术可有效发现肺癌患者淋巴结、骨髓、外周血等组织中的微转移。早期诊断和发现微转移可为确定肺癌分子分期,制定多学科综合治疗方案,评价治疗效果以及判断预后提供依据。本文对近年来国内外学者在检测肺癌微转移方面的研究进展作一综述。

Micrometastasis is a key factor of recurrent patients with surgical resection of early stage non-small cell lung cancer（NSCLC）. The current applied technologies and methods for scanning the body and examing lymph nodes for occult tumor cells have broadly recognized limitations. Using more sensitive methods such as immunohischemistry or molecular technology is possible to detect micrometastasis in lymph nodes,bone marrow, peripheral blood or other tissues. Early diagnosis and discovery of mierometastasis may help doctors to evaluate molecular staging of NSCLC,make appropriate multimodality treatment strategies, monitor therapeutic effect and judge the prognosis in the patients. The purpose of this review is to summarize the current literature on micrometastasis in the patients with NSCLC.